51社区黑料

by Sharon Mah

51社区黑料 Faculty of Health Sciences (51社区黑料FHS) Assistant Professor Kyle Burrows has been named Tier 2 Canada Research Chair (CRC) in Barrier Tissue Immunity and Chronic Inflammatory Disease. This award is the sixth CRC currently held at the Faculty of Health Sciences.

Burrows joined FHS in 2025 after completing a postdoctoral fellowship at the University of Toronto. His research focuses on how environmental microorganisms interact with the immune system at mucosal barrier surfaces, including the lungs and intestine. Despite growing recognition of the microbiome鈥檚 importance in health, relatively little is known about how mucosal immune cells interpret signals from environmental exposures, including the beneficial microbes that make up the body鈥檚 microbiome, to shape systemic immunity and influence the health of distant organs.

鈥淒iscovering the mechanisms by which commensal and environmental microorganisms trigger mucosal immune cells to enter circulation and influence tissue health or disease progression in other parts of the body could be key to understanding how chronic inflammation develops and persists,鈥� says Burrows. A deeper understanding of these interactions could have broad implications for chronic inflammatory and immune-mediated conditions, including asthma, arthritis, diabetes, multiple sclerosis, and cancer.

A major focus of Burrows鈥� research is a specialized immune cell population known as Group 2 innate lymphoid cells (ILC2s). These cells are abundant in barrier tissues such as the gut and lungs, where they play important roles in allergic responses and chronic inflammatory diseases. However, ILC2s are also found in non-barrier tissues including the liver, skin, central nervous system, and lymph nodes where they may adopt tissue-specific functions distinct from those observed in mucosal tissues. Emerging evidence suggests these cells contribute to diverse physiological processes, including metabolic and thermoregulation, as well as tissue repair, and wound healing. The diversity of ILC2s throughout the body raises the possibility that their function could be therapeutically modified, either through targeted interventions or by harnessing signals from the microbiome, to improve disease outcomes.

鈥淎 major challenge in treating chronic inflammatory diseases is that the same immune cell can behave very differently depending on the tissue environment,鈥� says Burrows. 鈥淏y understanding how these cells support healthy tissues and how those functions become disrupted we may uncover new opportunities to treat inflammation in a more targeted way.鈥�

It is in pursuit of this deeper understanding of the regulatory mechanisms of type 2 immunity, that Burrows will focus his Canada Research Chair program on three key projects:

1. How the microbiome shapes ILC2 responses and influences immunity across the body

This project will examine how signals from the body鈥檚 resident microbes regulate ILC2 activity and migration, and how ILC2s can, in turn, influence other resident immune cells in distant tissues. The goal is to understand how local microbial signals may have far-reaching effects on tissinue and immune function and contribute to chronic inflammatory diseases.

2. How ILC2s adapt and change their behaviour across different tissues

This work will investigate how ILC2s adjust their function depending on their tissue environment and the signals they receive. The focus is on understanding how these cells develop long-lasting, tissue-specific programs that shape immune balance in health and disease.

3. How type 2 immune cells contribute to anti-tumor immunity

This project will explore how ILC2s and related type 2 immune cells, function within the tumor environment and how they can either support or hinder anti-cancer immune responses. The goal is to identify ways these pathways could be harnessed to improve cancer immunotherapy.

This work builds on the results of his postdoctoral research, recently published by , which demonstrated that specialized epithelial (mucosal barrier) cells in the gut help regulate ILC2 activity by acting as a local control mechanism that tunes type 2 immune responses to maintain protection from protozoan parasites while preventing excessive inflammation.

鈥淭his study highlights a broader principle, that tissue-resident cell types can uniquely shape ILC2 function in ways that are tailored to the needs of each organ,鈥� says Burrows. 鈥淥nce we better understand these various signals, we may be able to disrupt or mimic specific interactions to limit the development and progression of chronic inflammatory diseases.鈥�

The Canada Research Chair program provides universities with the opportunity to recruit world-class scholars who are emerging global leaders in their field.